jordi bonaventura

Researching on drugs and brains. Also eating too much, traveling too little and collecting too many guitars..

[Institut de Neurociències de la UB @UBneuroscience]

#MultiBrainII | ✨Celebrating standout contributions and innovative research presented during the congress

Best Posters
🔸 71 | Giselle Priscilla
🔸 31 | Arianna Rizzo
🔸46 | Irene Rodríguez-Navarro

Best Flash Talk
🔹Mariarca Ascione

Check them out 🔗
https://t.co/sT8jLELPYQ

[Boris D Heifets @TheBorisLab]

Two patients in our care stopped having nightmares about their deceased children after a prolonged dream state induced by anesthesia. https://t.co/qdxONbYNXo @APAPubJournals, with @drpuppychow @PilleriinSikka et al.

[jordi bonaventura @jorgh82]

😱

[jordi bonaventura @jorgh82]

@SellesJoan Molts gràcies Joan, molt bon resum!

[Cell Press @CellPressNews]

"In vivo photopharmacology with light-activated opioid drugs" @NeuroCellPress @chromism https://t.co/X9oQsLzsiI

[Frontiers - Pharmacology and Toxicology @FrontPharmacol]

New Research: Converging circuits between pain and depression: the ventral tegmental area as a therapeutic hub #pharmacology https://t.co/HkJEi3j9uR

[jordi bonaventura @jorgh82]

@JLGomezPhD @mikelides @Pignatelli_Lab LOL

[jordi bonaventura @jorgh82]

Very happy to share this resource to the community: https://t.co/M0IvNfLF5D

[Eur Behav Pharm Soc. @EurBehavPharm]

Finally Symposia 18 "Novel tools and recent advances in the role of brain mu-opioid receptors in rewarding and aversive effects of drugs" is chaired by Jennifer Bossert, with talks by Emmanuel Darq, Jennifer Bossert, Marjorie Levinstein and @jorgh82

[jordi bonaventura @jorgh82]

A l'@ajigualada esporguen igual... No té sentit!

[Albert Giralt (Giralt lab) @neurocientific]

Are you a ketamine (research) lover? Do not miss the next speaker in our conferences' cycles in the Medical School. Dr. Bonaventura will talk about ketamine in the context of psychiatric disorders and some current controversies. @UBneuroscience @SENC_

[jordi bonaventura @jorgh82]

@diianni_t @UCSFPsychiatry @UCSF Congrats!!

[mike michaelides @mikelides]

New lab paper led by 1st author @eventrig (an exceptional NIDA Postbac currently applying to PhD programs) in collabo with @jorgh82. Brain exposure of opioids is a critical but somewhat neglected area of research with important mechanistic & human therapeutic implications.

[jordi bonaventura @jorgh82]

Potser Sants Bartomeu o Ignasi ho vindran a recollir, o aquell que sua sang...

[Marjorie Rose Levinstein @DrMarjorieRose]

Excited for my 1st postdoc paper! While [18F]FE-DPN and [3H]DPN are thought of as non-selective opioid radiotracers, they preferentially bind to mu opioid receptors in vivo. Thanks to @mikelides @jorgh82 @JLGomezPhD @eventrig @reecebudinich @cazaratejr
https://t.co/AzF6lAb8QD

[jordi bonaventura @jorgh82]

La primera riuada ja ha destrossat la via verda de la riera d’Òdena… aviam quan dura el biollac… @marccastells

[jordi bonaventura @jorgh82]

#ebfigd #ebfigd2022 @ Igualada https://t.co/mIOKqp2Wz0

[jordi bonaventura @jorgh82]

@keck_lab Indeed, although in this case it would take several metabolic steps back (some reports say norketamine is active though..). Stranger things happen in pharmacology!

[jordi bonaventura @jorgh82]

After several years and considerable ($$$) investment we could not find/validate any single/unique target for (2R,6R)-hydroxynorketamine: an elusive search https://t.co/FuFHn19844

[jordi bonaventura @jorgh82]

@keck_lab That is an interesting question since HNK would be normally be considered ‘end of route’ after desmethylation and hydroxylation of ketamine. Are you suggesting back-metabolism to the parent compound?